Generic Truseltiq Availability

Last updated on Jun 11, 2025.

Truseltiq is a brand name of infigratinib, approved by the FDA in the following formulation(s):

TRUSELTIQ (infigratinib phosphate - capsule;oral)

• Manufacturer: HELSINN HLTHCARE
  Approval date: May 28, 2021
  Strength(s): 25MG (discontinued) ^[RLD], 100MG (discontinued) ^[RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Truseltiq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Pharmaceutical dosage forms
  Patent 10,278,969
  Issued: May 7, 2019
  Inventor(s): Ribeiro Suzie
  Assignee(s): Novartis AG
  

  The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.

  Patent expiration dates:

  • December 11, 2034
    
    ✓ 
    Drug product
• Pharmaceutical dosage forms
  Patent 11,160,804
  Issued: November 2, 2021
  Inventor(s): Ribeiro Suzie Jesus
  Assignee(s): Novartis AG
  

  The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.

  Patent expiration dates:

  • December 11, 2034
    
    ✓ 
    Drug product
• Compounds and compositions as protein kinase inhibitors
  Patent 8,552,002
  Issued: October 8, 2013
  Inventor(s): Ding; Qiang et al.
  Assignee(s): Novartis AG (Basel, CH); IRM LLC (Hamilton, BM)
  

  The invention relates to compounds of formula (I) ##STR00001## wherein the substituents X.sup.1, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

  Patent expiration dates:

  • August 25, 2029
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
  Patent 9,067,896
  Issued: June 30, 2015
  Inventor(s): Berghausen Joerg & Kapa Prasad K & McKenna Joseph & Slade Joel & Wu Raeann & Du Zhengming & Stowasswer Frank
  Assignee(s): Novartis AG
  

  The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its monophosphoric acid salt, and the hydrochloride salt, including its dihydrate. The present technology further provides methods for preparing the various forms, compositions containing them, and methods of treatment employing them.

  Patent expiration dates:

  • August 6, 2028
    
    ✓ 
    Drug substance

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • May 28, 2026 - NEW CHEMICAL ENTITY
  • May 28, 2028 - FOR TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer